Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Purchased by Woodline Partners LP

Woodline Partners LP raised its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 20.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 300,504 shares of the company’s stock after purchasing an additional 50,000 shares during the period. Woodline Partners LP owned 1.02% of Dianthus Therapeutics worth $6,551,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in DNTH. R Squared Ltd acquired a new position in shares of Dianthus Therapeutics in the 4th quarter valued at $26,000. KLP Kapitalforvaltning AS purchased a new stake in Dianthus Therapeutics in the fourth quarter valued at $33,000. KBC Group NV acquired a new position in Dianthus Therapeutics in the fourth quarter valued at $35,000. BNP Paribas Financial Markets purchased a new position in shares of Dianthus Therapeutics during the fourth quarter worth about $59,000. Finally, AlphaQuest LLC increased its position in shares of Dianthus Therapeutics by 273.1% during the fourth quarter. AlphaQuest LLC now owns 4,197 shares of the company’s stock worth $91,000 after purchasing an additional 3,072 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Trading Up 0.3%

NASDAQ:DNTH opened at $18.42 on Friday. Dianthus Therapeutics, Inc. has a 12-month low of $13.37 and a 12-month high of $32.27. The stock’s 50 day simple moving average is $19.13 and its 200-day simple moving average is $21.83. The firm has a market cap of $592.39 million, a P/E ratio of -7.37 and a beta of 1.48.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.04. The firm had revenue of $1.16 million for the quarter, compared to analyst estimates of $0.81 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. Research analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Analysts Set New Price Targets

DNTH has been the subject of several research reports. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Tuesday, May 13th. Guggenheim reissued a “buy” rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Robert W. Baird lowered their target price on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 13th. Finally, Wedbush reiterated an “outperform” rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $53.00.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.